NEU.INH_VIP.develop_niche: Studies — page 13
How association tiers are defined — cell–trait and gene–trait
SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.
Cell–trait tiers
- Cell–trait links
- Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
- Required for Specific or Relevant
- The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
- Specific (Tier 1)
- Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
- Relevant (Tier 2)
- Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
- Interpretation and report values
- CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
- Meta traits and individual traits
- Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.
Gene–trait priorities (variant–tCRE–gene evidence)
- Variant–tCRE–gene links
- Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
- Required genetic support
- The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
- Required cellular support
- The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
- High priority
- Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
- Medium priority
- Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
- Same-record evidence and aggregation
- Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
- Limits of interpretation
- A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.
State · 122 full-atlas cells · all tissues.
Marker genes and cell annotation · Open this population in Cell Browser →
ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.
Rows 12,001–12,313 of 12,313; ranked by score descending. Equal values use name/identifier order.
| # | Trait / study | Individual trait ID | Mean IC score |
|---|---|---|---|
| 12001 | CPXM1/MDK ratio | GCST90314221 | 2.81e-06 |
| 12002 | MMP3 levels | GCST90469920 | 2.81e-06 |
| 12003 | Total lipids in very large VLDL | GCST90500607 | 2.79e-06 |
| 12004 | Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI) | GCST003658 | 2.77e-06 |
| 12005 | CEACAM6 levels | GCST90468697 | 2.75e-06 |
| 12006 | DNAJB1/PPME1 ratio | GCST90314510 | 2.72e-06 |
| 12007 | White blood cell count | GCST90002374 | 2.71e-06 |
| 12008 | Triglycerides in VLDL | GCST90500295 | 2.69e-06 |
| 12009 | DKK1 levels | GCST90468997 | 2.68e-06 |
| 12010 | AXIN1/SRPK2 ratio | GCST90313417 | 2.64e-06 |
| 12011 | Red blood cell erythrocyte distribution width (UKB data field 30070) | GCST90468099 | 2.63e-06 |
| 12012 | HPGDS/ITGAV ratio | GCST90315080 | 2.60e-06 |
| 12013 | CD164/CD99 ratio | GCST90313740 | 2.59e-06 |
| 12014 | PDGFB/TNFSF13 ratio | GCST90315632 | 2.54e-06 |
| 12015 | DCTN1 levels | GCST90468958 | 2.54e-06 |
| 12016 | IL1R1/IL1RN ratio | GCST90315158 | 2.52e-06 |
| 12017 | DSC2 levels | GCST90469040 | 2.51e-06 |
| 12018 | Heart rate variability (corrected root mean square of successive differences) | GCST90281264 | 2.48e-06 |
| 12019 | CHI3L1 levels | GCST90468743 | 2.47e-06 |
| 12020 | DKK1/SERPINE1 ratio | GCST90314480 | 2.46e-06 |
| 12021 | CD300E/EFNA4 ratio | GCST90313797 | 2.43e-06 |
| 12022 | ATXN2L levels | GCST90468402 | 2.43e-06 |
| 12023 | MPIG6B levels | GCST90469935 | 2.39e-06 |
| 12024 | DDR1/PVR ratio | GCST90314442 | 2.39e-06 |
| 12025 | CXCL16 levels | GCST90468928 | 2.39e-06 |
| 12026 | CCL27 levels | GCST90468579 | 2.36e-06 |
| 12027 | CCL5/SELP ratio | GCST90313705 | 2.36e-06 |
| 12028 | ERBB4/NELL1 ratio | GCST90314691 | 2.35e-06 |
| 12029 | SDC4 levels | GCST90470559 | 2.34e-06 |
| 12030 | EDAR/YES1 ratio | GCST90314594 | 2.25e-06 |
| 12031 | CD248 levels | GCST90468612 | 2.23e-06 |
| 12032 | CEP43/TIA1 ratio | GCST90314021 | 2.22e-06 |
| 12033 | DPP4 levels | GCST90469033 | 2.22e-06 |
| 12034 | Diacylglycerol_36:3_[M+H-H2O]1+ levels | GCST90060189 | 2.22e-06 |
| 12035 | ENPP6 levels | GCST90469117 | 2.22e-06 |
| 12036 | Chronic diseases of tonsils and adenoids | FING00000283 | 2.21e-06 |
| 12037 | Basophil count | GCST90002292 | 2.18e-06 |
| 12038 | Neutrophil percentage of white cells | GCST90002399 | 2.18e-06 |
| 12039 | Myasthenia gravis | GCST90093061 | 2.17e-06 |
| 12040 | Free Cholesterol to Total Lipids in Very Large VLDL percentage | GCST90500593 | 2.15e-06 |
| 12041 | PCDHB15 levels | GCST90470173 | 2.15e-06 |
| 12042 | HRC levels | GCST90469475 | 2.14e-06 |
| 12043 | PDGFA levels | GCST90470188 | 2.13e-06 |
| 12044 | GLOD4/HSPA1A ratio | GCST90314937 | 2.10e-06 |
| 12045 | PLXNB2 levels | GCST90242299 | 2.09e-06 |
| 12046 | LGALS3BP levels | GCST90469760 | 2.08e-06 |
| 12047 | FAP levels | GCST90469189 | 2.04e-06 |
| 12048 | KLRK1 levels | GCST90469713 | 2.03e-06 |
| 12049 | ATP5IF1/LYN ratio | GCST90313389 | 1.98e-06 |
| 12050 | Sphingomyelin_32:1_[M+H]1+ levels | GCST90060225 | 1.98e-06 |
| 12051 | Job involved shift work | Employment history | UKBB00000382 | 1.97e-06 |
| 12052 | Other joint disorders | FING00001064 | 1.94e-06 |
| 12053 | Monocyte count | GCST90002341 | 1.94e-06 |
| 12054 | BMP4 levels | GCST90468453 | 1.94e-06 |
| 12055 | CD93/TNFRSF4 ratio | GCST90313922 | 1.92e-06 |
| 12056 | COLEC12/TAFA5 ratio | GCST90314185 | 1.89e-06 |
| 12057 | GCNT1 levels | GCST90469319 | 1.86e-06 |
| 12058 | PTPRC levels | GCST90470380 | 1.85e-06 |
| 12059 | Alzheimer's disease or family history of Alzheimer's disease | GCST007320 | 1.84e-06 |
| 12060 | CPQ levels | GCST90468846 | 1.84e-06 |
| 12061 | Bone marrow fat fraction of lumbar vertebra 4 | GCST90652389 | 1.83e-06 |
| 12062 | T1 CAT volume L PlanumPolare | GCST90384086 | 1.77e-06 |
| 12063 | ALB levels | UKBB00000019 | 1.77e-06 |
| 12064 | CD86 levels | GCST90468654 | 1.77e-06 |
| 12065 | CERT/MAX ratio | GCST90314028 | 1.77e-06 |
| 12066 | CD99/RELT ratio | GCST90313930 | 1.75e-06 |
| 12067 | ADAM9 levels | GCST90468221 | 1.73e-06 |
| 12068 | Late-onset myasthenia gravis | GCST90093466 | 1.70e-06 |
| 12069 | ROBO1 levels | GCST90470489 | 1.66e-06 |
| 12070 | Neutrophill percentage (UKB data field 30200) | GCST90468093 | 1.64e-06 |
| 12071 | MMP3 levels | GCST90012027 | 1.64e-06 |
| 12072 | Concentration of chylomicrons and extremely large VLDL particles | GCST90501015 | 1.63e-06 |
| 12073 | TNFSF12/TNFSF13 ratio | GCST90315941 | 1.61e-06 |
| 12074 | ANGPT1 levels | GCST90468300 | 1.60e-06 |
| 12075 | SPARC levels | GCST90470718 | 1.59e-06 |
| 12076 | BCAM/PCDH17 ratio | GCST90313475 | 1.58e-06 |
| 12077 | Leiomyoma of uterus | FING00000719 | 1.58e-06 |
| 12078 | DAG1/DKK1 ratio | GCST90314373 | 1.56e-06 |
| 12079 | ATP5IF1/FIS1 ratio | GCST90313385 | 1.56e-06 |
| 12080 | VMO1 levels | GCST90471042 | 1.56e-06 |
| 12081 | PDCD1/TNFRSF4 ratio | GCST90315609 | 1.55e-06 |
| 12082 | Platelet count | GCST90278640 | 1.53e-06 |
| 12083 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T111 | ECGU000111 | 1.52e-06 |
| 12084 | Triglycerides to Total Lipids in Very Large VLDL percentage | GCST90500692 | 1.50e-06 |
| 12085 | EGF/MPIG6B ratio | GCST90314611 | 1.48e-06 |
| 12086 | F11R/TMSB10 ratio | GCST90314729 | 1.47e-06 |
| 12087 | IDP T1 FAST ROIs L cerebellum crus II | GCST90002572 | 1.45e-06 |
| 12088 | SORT1/ST6GAL1 ratio | GCST90315869 | 1.45e-06 |
| 12089 | HYOU1 levels | GCST90469496 | 1.43e-06 |
| 12090 | Granulocyte percentage of myeloid white cells | GCST004608 | 1.43e-06 |
| 12091 | ADGRE5 levels | GCST90468238 | 1.42e-06 |
| 12092 | Cholesteryl Esters to Total Lipids in Large VLDL percentage | GCST90498162 | 1.40e-06 |
| 12093 | White blood cell count | GCST90002407 | 1.39e-06 |
| 12094 | Omega-6 fatty acids to total fatty acids percentage | GCST90502121 | 1.37e-06 |
| 12095 | HIP1R levels | GCST90469453 | 1.33e-06 |
| 12096 | Platelet crit | Blood count | UKBB00000647 | 1.32e-06 |
| 12097 | Triacylglycerol_56:7_[M+NH4]1+ levels | GCST90060551 | 1.32e-06 |
| 12098 | rfMRI connectivity (ICA100 edge 387) | GCST90005240 | 1.28e-06 |
| 12099 | CD302 levels | GCST90468624 | 1.26e-06 |
| 12100 | ALB levels | GCST90278616 | 1.25e-06 |
| 12101 | CD69/CEP43 ratio | GCST90313867 | 1.21e-06 |
| 12102 | aparc-DKTatlas lh area parstriangularis | GCST90003252 | 1.21e-06 |
| 12103 | Renal failure | FING00001250 | 1.20e-06 |
| 12104 | CD33 levels | GCST90468625 | 1.20e-06 |
| 12105 | ALB levels | GCST90497108 | 1.19e-06 |
| 12106 | KLRF1 levels | GCST90469712 | 1.18e-06 |
| 12107 | CLEC1B/SORT1 ratio | GCST90314104 | 1.16e-06 |
| 12108 | triglyceride (maximum, inv-norm transformed) | GCST90476431 | 1.16e-06 |
| 12109 | SUSD1 levels | GCST90470786 | 1.14e-06 |
| 12110 | Tyrosine levels | GCST90500156 | 1.14e-06 |
| 12111 | CLEC7A levels | GCST90468778 | 1.13e-06 |
| 12112 | CCL11 levels | GCST90468564 | 1.12e-06 |
| 12113 | LYN levels | GCST90469826 | 1.09e-06 |
| 12114 | Polyp of the female genital tract | FING00001190 | 1.07e-06 |
| 12115 | CNPY4 levels | GCST90468800 | 1.06e-06 |
| 12116 | Skin red/green component | GCST90320258 | 1.05e-06 |
| 12117 | Neutrophill percentage | Blood count | UKBB00000498 | 1.05e-06 |
| 12118 | CFP levels | GCST90468731 | 1.04e-06 |
| 12119 | Phospholipids to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501050 | 1.04e-06 |
| 12120 | ICOSLG levels | GCST90469503 | 1.03e-06 |
| 12121 | CD74/TIMD4 ratio | GCST90313896 | 1.02e-06 |
| 12122 | Neutrophil count | GCST90002351 | 9.94e-07 |
| 12123 | GFRA2 levels | GCST90469329 | 9.80e-07 |
| 12124 | FAP/LRRN1 ratio | GCST90314783 | 9.75e-07 |
| 12125 | SELL levels | GCST90470567 | 9.70e-07 |
| 12126 | Neutrophill count (UKB data field 30140) | GCST90468092 | 9.46e-07 |
| 12127 | COLEC12/TNFRSF1A ratio | GCST90314187 | 9.42e-07 |
| 12128 | White blood cell (leukocyte) count | Blood count | UKBB00000913 | 9.29e-07 |
| 12129 | NECTIN4 levels | GCST90470021 | 9.06e-07 |
| 12130 | VEGFB levels | GCST90471035 | 9.03e-07 |
| 12131 | CD300C/CLEC14A ratio | GCST90313786 | 9.01e-07 |
| 12132 | FCGR3B levels | GCST90469202 | 8.95e-07 |
| 12133 | ARSB levels | GCST90468369 | 8.91e-07 |
| 12134 | FABP2/RBP2 ratio | GCST90314757 | 8.82e-07 |
| 12135 | AMIGO2 levels | GCST90468292 | 8.79e-07 |
| 12136 | ADGRE5/ITGB2 ratio | GCST90313180 | 8.74e-07 |
| 12137 | Total Lipids in VLDL | GCST90500236 | 8.70e-07 |
| 12138 | APP/NID1 ratio | GCST90313326 | 8.65e-07 |
| 12139 | SHBG levels | GCST90470622 | 8.59e-07 |
| 12140 | SELP levels | GCST90470569 | 8.42e-07 |
| 12141 | ENPP5 levels | GCST90469116 | 8.41e-07 |
| 12142 | Neutrophil count | GCST90002398 | 8.30e-07 |
| 12143 | LIFR levels | GCST90469769 | 8.20e-07 |
| 12144 | Sporadic miscarriage | GCST011888 | 8.06e-07 |
| 12145 | SERPINE1 levels | GCST90470596 | 7.99e-07 |
| 12146 | LAT2/MANF ratio | GCST90315277 | 7.94e-07 |
| 12147 | SNAP23/ZBTB16 ratio | GCST90315858 | 7.94e-07 |
| 12148 | CD4 levels | GCST90468636 | 7.91e-07 |
| 12149 | NCAN levels | GCST90470005 | 7.74e-07 |
| 12150 | FURIN/PLA2G15 ratio | GCST90314887 | 7.64e-07 |
| 12151 | White blood cell count | GCST004610 | 7.33e-07 |
| 12152 | Osteoporosis, osteopenia and pathological fracture (PheCode 743) | GCST90476258 | 6.63e-07 |
| 12153 | L1CAM levels | GCST90469723 | 6.53e-07 |
| 12154 | NECTIN4/TGFBR2 ratio | GCST90315535 | 6.50e-07 |
| 12155 | PALM3 levels | GCST90470153 | 6.49e-07 |
| 12156 | NOTCH2 levels | GCST90470066 | 6.34e-07 |
| 12157 | LDLR levels | GCST90469750 | 6.33e-07 |
| 12158 | BA-exvivo lh area BA45 | GCST90003215 | 6.31e-07 |
| 12159 | Alzheimer's disease (MTAG) | GCST90449060 | 6.24e-07 |
| 12160 | Triglycerides to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501092 | 6.10e-07 |
| 12161 | DPP10 levels | GCST90469032 | 6.05e-07 |
| 12162 | ICAM3/SLAMF7 ratio | GCST90315123 | 5.61e-07 |
| 12163 | Telomere length (principal component 1) | GCST90435144 | 5.52e-07 |
| 12164 | COMP/MYOC ratio | GCST90314191 | 5.51e-07 |
| 12165 | GHR levels | GCST90469342 | 5.44e-07 |
| 12166 | CRTAM/PDCD1 ratio | GCST90314279 | 5.35e-07 |
| 12167 | Hemangioma of skin and subcutaneous tissue (PheCode 228.1) | GCST90475633 | 5.20e-07 |
| 12168 | APP/DAG1 ratio | GCST90313320 | 4.98e-07 |
| 12169 | LGALS9/SIGLEC1 ratio | GCST90315323 | 4.96e-07 |
| 12170 | SIGLEC1 levels | GCST90470632 | 4.76e-07 |
| 12171 | aseg global volume EstimatedTotalIntraCranial | GCST90002597 | 4.74e-07 |
| 12172 | TNF levels | GCST90470924 | 4.57e-07 |
| 12173 | TNFRSF6B levels | GCST90470914 | 4.54e-07 |
| 12174 | MAVS/PPP1R9B ratio | GCST90315393 | 4.53e-07 |
| 12175 | Alzheimer's disease (MTAG) | GCST90449053 | 4.53e-07 |
| 12176 | Tyrosine levels (UKB data field 23469) | GCST90269566 | 4.43e-07 |
| 12177 | PTP4A3 levels | GCST90470375 | 4.35e-07 |
| 12178 | Ulcerative proctitis | FING00001393 | 4.34e-07 |
| 12179 | ITGB1BP2/SKAP2 ratio | GCST90315219 | 4.28e-07 |
| 12180 | KLK13 levels | GCST90469699 | 4.23e-07 |
| 12181 | BCAM/CLEC14A ratio | GCST90313470 | 4.19e-07 |
| 12182 | HBEGF levels | GCST90469433 | 4.19e-07 |
| 12183 | JAM2/TNFRSF21 ratio | GCST90315242 | 4.13e-07 |
| 12184 | LUZP2 levels | GCST90469819 | 4.08e-07 |
| 12185 | APP levels | GCST90468344 | 4.07e-07 |
| 12186 | SEZ6L2 levels | GCST90470606 | 4.00e-07 |
| 12187 | ERBB3 levels | GCST90469140 | 3.96e-07 |
| 12188 | MANSC4 levels | GCST90469848 | 3.82e-07 |
| 12189 | VAMP8 levels | GCST90471025 | 3.79e-07 |
| 12190 | Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500929 | 3.55e-07 |
| 12191 | FCN2 levels | GCST90469204 | 3.44e-07 |
| 12192 | MCTS1 levels | GCST90469874 | 3.43e-07 |
| 12193 | CD163/IL18BP ratio | GCST90313736 | 3.34e-07 |
| 12194 | ACVRL1/EFNA4 ratio | GCST90313156 | 3.30e-07 |
| 12195 | TNFSF12 levels | GCST90470919 | 3.26e-07 |
| 12196 | Omega-6 fatty acids levels | GCST90499177 | 3.23e-07 |
| 12197 | ACP5 levels | GCST90468203 | 3.19e-07 |
| 12198 | FAM3B/FUT3_FUT5 ratio | GCST90314777 | 3.18e-07 |
| 12199 | FCRLB levels | GCST90469210 | 3.03e-07 |
| 12200 | FABP4/FGF21 ratio | GCST90314758 | 3.03e-07 |
| 12201 | IL1RN/LGALS9 ratio | GCST90315160 | 2.93e-07 |
| 12202 | Deviated nasal septum | FING00000409 | 2.88e-07 |
| 12203 | Other bacterial intestinal infections | FING00000969 | 2.80e-07 |
| 12204 | CD59/CST6 ratio | GCST90313857 | 2.67e-07 |
| 12205 | Epstein-Barr virus ZEBRA antibody levels | GCST90006901 | 2.58e-07 |
| 12206 | SRPK2/VASH1 ratio | GCST90315886 | 2.56e-07 |
| 12207 | CCL5/RARRES2 ratio | GCST90313704 | 2.55e-07 |
| 12208 | Cholesteryl Esters to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500956 | 2.55e-07 |
| 12209 | ADA2 levels | GCST90468215 | 2.48e-07 |
| 12210 | NBL1/NECTIN4 ratio | GCST90315514 | 2.48e-07 |
| 12211 | FSTL3/LTBR ratio | GCST90314883 | 2.46e-07 |
| 12212 | Forced expiratory volume in 1-second (FEV1), predicted percentage | Spirometry | UKBB00000253 | 2.40e-07 |
| 12213 | CDH3/NECTIN4 ratio | GCST90313952 | 2.30e-07 |
| 12214 | CD74/JAM2 ratio | GCST90313893 | 2.28e-07 |
| 12215 | CLEC4G/KEL ratio | GCST90314119 | 2.26e-07 |
| 12216 | PDLIM7/SRC ratio | GCST90315639 | 2.24e-07 |
| 12217 | DNAJB1/METAP2 ratio | GCST90314509 | 2.23e-07 |
| 12218 | NPTX1 levels | GCST90470078 | 2.13e-07 |
| 12219 | CLEC4A levels | GCST90468771 | 2.10e-07 |
| 12220 | Other and unspecified rosacea | FING00000951 | 2.08e-07 |
| 12221 | Total lipid levels in chylomicrons and extremely large VLDL | GCST90501002 | 2.03e-07 |
| 12222 | ERBB2/FURIN ratio | GCST90314686 | 2.02e-07 |
| 12223 | Tyrosine levels | GCST90500143 | 1.92e-07 |
| 12224 | SLAMF7 levels | GCST90470651 | 1.91e-07 |
| 12225 | ASPN levels | GCST90468377 | 1.90e-07 |
| 12226 | TFRC levels | GCST90451684 | 1.78e-07 |
| 12227 | CD19 on IgD- CD38- B cell | GCST90001733 | 1.78e-07 |
| 12228 | CCL13 levels | GCST90468565 | 1.74e-07 |
| 12229 | IGF2R levels | GCST90469526 | 1.64e-07 |
| 12230 | CA6 levels | GCST90468515 | 1.64e-07 |
| 12231 | APP/HBEGF ratio | GCST90313324 | 1.59e-07 |
| 12232 | OSMR levels | GCST90470132 | 1.58e-07 |
| 12233 | CD40LG levels | GCST90468632 | 1.48e-07 |
| 12234 | Hydrocele | FING00000627 | 1.44e-07 |
| 12235 | AmygNuclei rh volume Basal-nucleus | GCST90002659 | 1.41e-07 |
| 12236 | PDGFB levels | GCST90470189 | 1.41e-07 |
| 12237 | LRP1 levels | GCST90469797 | 1.41e-07 |
| 12238 | IL27 levels | GCST90469060 | 1.31e-07 |
| 12239 | Concentration of chylomicrons and extremely large VLDL particles | GCST90501010 | 1.24e-07 |
| 12240 | EGF/MANF ratio | GCST90314609 | 1.20e-07 |
| 12241 | Red cell distribution width | GCST90025988 | 1.10e-07 |
| 12242 | Neutrophill count | Blood count | UKBB00000497 | 1.06e-07 |
| 12243 | ALDH1A1/RBKS ratio | GCST90313247 | 1.02e-07 |
| 12244 | F11R/SORT1 ratio | GCST90314726 | 1.01e-07 |
| 12245 | COMP levels | GCST90468827 | 9.95e-08 |
| 12246 | Heart failure and bmi 25plus | FING00000603 | 9.89e-08 |
| 12247 | CSF1R levels | GCST90468880 | 9.60e-08 |
| 12248 | NID2 levels | GCST90470048 | 9.43e-08 |
| 12249 | MICB_MICA/TEK ratio | GCST90315446 | 8.86e-08 |
| 12250 | Hidradenitis suppurativa | FING00000621 | 8.26e-08 |
| 12251 | MYH9 levels | GCST90469975 | 7.71e-08 |
| 12252 | ACVRL1 levels | GCST90468211 | 7.58e-08 |
| 12253 | Omega-6 fatty acids to total fatty acids percentage | GCST90502528 | 7.55e-08 |
| 12254 | CD244/GP1BA ratio | GCST90313766 | 7.53e-08 |
| 12255 | Other cancer | GCST90475181 | 7.49e-08 |
| 12256 | BACH1/DIABLO ratio | GCST90313437 | 6.61e-08 |
| 12257 | PLXNA4 levels | GCST90470265 | 6.52e-08 |
| 12258 | GP1BA/SDC4 ratio | GCST90314957 | 6.49e-08 |
| 12259 | White blood cell count (basophil) | GCST004618 | 6.47e-08 |
| 12260 | ULBP2 levels | GCST90471008 | 6.32e-08 |
| 12261 | Left-hemisphere somatomotor network to left-hemisphere somatomotor network white-matter structural connectivity | GCST90302669 | 5.97e-08 |
| 12262 | Tyrosine levels | GCST90092993 | 5.96e-08 |
| 12263 | Myeloid white cell count | GCST004626 | 5.69e-08 |
| 12264 | VIT levels | GCST90471041 | 5.64e-08 |
| 12265 | GSN levels | GCST90469409 | 5.52e-08 |
| 12266 | Basophil percentage of white cells | GCST004631 | 5.50e-08 |
| 12267 | Glutamine levels | GCST90497285 | 5.36e-08 |
| 12268 | HEPACAM2 levels | GCST90469445 | 4.89e-08 |
| 12269 | LY9 levels | GCST90469824 | 4.38e-08 |
| 12270 | NECTIN2 levels | GCST90470020 | 4.18e-08 |
| 12271 | AKR7L levels | GCST90468275 | 3.63e-08 |
| 12272 | TNFSF13 levels | GCST90470921 | 3.55e-08 |
| 12273 | IFNAR1 levels | GCST90469512 | 3.44e-08 |
| 12274 | LYVE1 levels | GCST90469832 | 3.22e-08 |
| 12275 | ADGRE5/SEMA7A ratio | GCST90313183 | 3.17e-08 |
| 12276 | FGFR2 levels | GCST90469233 | 2.52e-08 |
| 12277 | Sum basophil neutrophil counts | GCST004620 | 2.47e-08 |
| 12278 | Neutrophil count | GCST004629 | 2.37e-08 |
| 12279 | Sum neutrophil eosinophil counts | GCST004613 | 1.91e-08 |
| 12280 | Etiocholanolone glucuronide levels | GCST90199964 | 1.86e-08 |
| 12281 | NADK levels | GCST90469993 | 1.80e-08 |
| 12282 | ESAM levels | GCST90469152 | 1.71e-08 |
| 12283 | SDC4/SMAD1 ratio | GCST90315820 | 1.70e-08 |
| 12284 | Peptic ulcer (excl. esophageal) | digestive | UKBB00000639 | 1.66e-08 |
| 12285 | SEMA7A levels | GCST90470575 | 1.60e-08 |
| 12286 | Granulocyte count | GCST004614 | 1.53e-08 |
| 12287 | White blood cell count | GCST90278647 | 1.46e-08 |
| 12288 | DNAJA2/HPCAL1 ratio | GCST90314503 | 1.44e-08 |
| 12289 | SDC4/WWP2 ratio | GCST90315821 | 1.43e-08 |
| 12290 | INHBB levels | GCST90469614 | 1.35e-08 |
| 12291 | MDK levels | GCST90469877 | 1.31e-08 |
| 12292 | DPP4/ITGB1 ratio | GCST90314540 | 1.28e-08 |
| 12293 | CRHBP levels | GCST90468860 | 9.08e-09 |
| 12294 | Basophil percentage of granulocytes | GCST004634 | 7.80e-09 |
| 12295 | TIMD4 levels | GCST90470866 | 6.60e-09 |
| 12296 | NRCAM levels | GCST90470082 | 5.92e-09 |
| 12297 | ADGRE5/NOTCH1 ratio | GCST90313181 | 5.73e-09 |
| 12298 | COLEC12/LTBR ratio | GCST90314182 | 4.15e-09 |
| 12299 | F11R levels | GCST90469164 | 4.04e-09 |
| 12300 | CDHR2/SSC4D ratio | GCST90313965 | 3.95e-09 |
| 12301 | LTBR/SIRPB1 ratio | GCST90315339 | 3.56e-09 |
| 12302 | ACP6 levels | GCST90468204 | 3.29e-09 |
| 12303 | ADGRE5/VCAM1 ratio | GCST90313184 | 3.28e-09 |
| 12304 | CDH5 levels | GCST90468676 | 3.13e-09 |
| 12305 | SDK2 levels | GCST90470562 | 2.21e-09 |
| 12306 | LGALS3 levels | GCST90469761 | 1.87e-09 |
| 12307 | X-21829 levels | GCST90200585 | 6.44e-10 |
| 12308 | HSPB1/QDPR ratio | GCST90315089 | 5.91e-10 |
| 12309 | KEL levels | GCST90469673 | 3.85e-10 |
| 12310 | CLEC1A/CLEC7A ratio | GCST90314083 | 3.21e-10 |
| 12311 | DSG3/NECTIN4 ratio | GCST90314560 | 1.43e-10 |
| 12312 | CCL24 levels | GCST90468576 | 5.63e-11 |
| 12313 | CD163/DSC2 ratio | GCST90313733 | 8.60e-12 |